Importantly, the PAM activity of Compound 1 was equivalent for CCK-58 that is the predominant circulating form of CCK, and for augmentation of CCK signaling at rat and monkey CCK1R that represent critical animal models for preclinical assessment of potential anti-obesity drug (8). This evidence concerns the gene CCK and obesity due to melanocortin 4 receptor deficiency.